CWC
VRCA icon

Carolinas Wealth Consulting’s Verrica Pharmaceuticals VRCA Stock Holding History

Carolinas Wealth Consulting’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13
Closed -$1K – 1036
2020
Q3 		$1K Hold
13
– – ﹤0.01% 895
2020
Q2 		$1K Buy
+13
New +$1.5K ﹤0.01% 624

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Carolinas Wealth Consulting's VRCA Position: Q4 2020 in Review

Carolinas Wealth Consulting sold out of Verrica Pharmaceuticals (VRCA) in Q4 2020, closing a stake of 13 shares — an estimated $1K sold.

Carolinas Wealth Consulting first reported a position in VRCA in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 44 funds tracked by Wall St. Rank hold VRCA as of Q4 2020.

  • Carolinas Wealth Consulting reported no remaining Verrica Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 13 Verrica Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Carolinas Wealth Consulting first reported a position in Verrica Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Carolinas Wealth Consulting's Verrica Pharmaceuticals position peaked at $1K in Q3 2020.
  • 44 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2020, filed 16 Feb 2021.